Skip to main content
Livermore
Livermore
ZHEN

Parian Global Management LP

SEC CIK
0001752148
Latest filing
Nov 14, 2022

The latest 13F from Parian Global Management LP covers Q3 2022 (filed Nov 14, 2022): 32 long positions worth $30.8M. The top 10 holdings make up 72.2% of the portfolio, and the largest is CVRx, Inc. (CVRX) at 11.9%. Livermore has 7 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q3 2022

Share counts compared with Q2 2022: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
20
Est. +$10.1M
Added
6
Est. +$2.22M
Reduced
6
Est. −$4.73M
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. CVRXCVRx, Inc.
    11.9%$3.67MHistory
  2. APENApollo Endosurgery, Inc.
    9.4%$2.90MHistory
  3. IRTCiRhythm Holdings, Inc.
    9.3%$2.86MHistory
  4. STIMNeuronetics, Inc.
    8.6%$2.64MHistory
  5. ATECAlphatec Holdings, Inc.
    7.6%$2.32MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. NOTVInotiv, Inc.
    +$2.31MNewHistory
  2. AIRSAirsculpt Technologies, Inc.
    +$1.06MNewHistory
  3. TKNOAlpha Teknova, Inc.
    +$969.0KNewHistory
  4. VRAYViewRay, Inc.
    +$965.0KNewHistory
  5. IRTCiRhythm Holdings, Inc.
    +$721.5KAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. NOTVInotiv, Inc.
    +7.50 pp0.0% → 7.5%History
  2. AIRSAirsculpt Technologies, Inc.
    +3.45 pp0.0% → 3.4%History
  3. TKNOAlpha Teknova, Inc.
    +3.15 pp0.0% → 3.2%History
  4. VRAYViewRay, Inc.
    +3.14 pp0.0% → 3.1%History
  5. ACVAACV Auctions Inc.
    +2.04 pp0.0% → 2.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CVRXCVRx, Inc.
    −$1.28MReducedHistory
  2. APENApollo Endosurgery, Inc.
    −$1.13MReducedHistory
  3. SERASera Prognostics, Inc.
    −$910.3KReducedHistory
  4. CELLBruker Cellular Analysis, Inc.
    −$835.0KReducedHistory
  5. VAPOVapotherm Inc
    −$303.4KReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. VAPOVapotherm Inc
    −9.85 pp15.9% → 6.0%History
  2. CELLBruker Cellular Analysis, Inc.
    −7.85 pp8.7% → 0.8%History
  3. SERASera Prognostics, Inc.
    −4.62 pp5.4% → 0.8%History
  4. RNLXYRenalytix plc
    −3.67 pp4.4% → 0.8%History
  5. APENApollo Endosurgery, Inc.
    −2.80 pp12.2% → 9.4%History

Metrics

13F metrics for Q3 2022, computed only from the numbers in the filings. Definitions below.

Portfolio value
$30.8M
+$8.92M (+40.8%) vs. prior quarter
Positions
32
+20 vs. prior quarter
Top 10 concentration
72.2%
Top 10 as share of value
Turnover
18.0%
Q3 2022, one quarter
Average holding period
4.1 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

7 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $220.4M (Q2 2021)

Q1 2021: $214.5MQ2 2021: $220.4MQ3 2021: $139.6MQ4 2021: $110.4MQ1 2022: $48.5MQ2 2022: $21.8MQ3 2022: $30.8M
Q1 2021Q3 2022
13F filings of Parian Global Management LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2022Nov 14, 202232$30.8MCVRXAPENIRTCvs. Q2 2022SEC
Q2 2022Aug 15, 202212$21.8MVAPOCVRXAPENvs. Q1 2022SEC
Q1 2022May 16, 202212$48.5MVAPOAPENSERAvs. Q4 2021SEC
Q4 2021Feb 14, 202225$110.4MVAPORNLXYAPENvs. Q3 2021SEC
Q3 2021Nov 15, 202128$139.6MVAPOSERARNLXYvs. Q2 2021SEC
Q2 2021Aug 16, 202138$220.4MVAPORNLXYPAYOvs. Q1 2021SEC
Q1 2021May 17, 202130$214.5MVAPORNLXYHAPN–SEC

13D and 13G filings

Companies where Parian Global Management LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Parian Global Management LP does not currently report owning 5% or more of any company.

Latest filings

14 filings on file made by Parian Global Management LP or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Parian Global Management LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
STIMNeuronetics, Inc.Nov 14, 202411:32 AM ET13G/A0.00%0 shares–Below 5%Jun 1, 2023SEC
VAPOVapotherm IncNov 14, 202410:26 AM ET13G/A0.00%0 shares–Below 5%Sep 30, 2024SEC
VAPOVapotherm IncFeb 14, 202413G/AOld format–––SEC
STIMNeuronetics, Inc.Feb 13, 202313G/AOld format–––SEC
VAPOVapotherm IncFeb 13, 202313G/AOld format–––SEC
STIMNeuronetics, Inc.Feb 9, 202213GOld format–New–SEC
HUMAHumacyte, Inc.Feb 9, 202213G/AOld format–––SEC
ARTLArtelo Biosciences, Inc.Feb 9, 202213G/AOld format–––SEC
VAPOVapotherm IncFeb 9, 202213G/AOld format–––SEC
ACTGAcacia Research CorpJun 24, 202113G/AOld format–––SEC
ARTLArtelo Biosciences, Inc.Mar 1, 202113GOld format–New–SEC
HUMAHumacyte, Inc.Mar 1, 202113GOld format–New–SEC
ACTGAcacia Research CorpFeb 18, 202113GOld format–New–SEC
VAPOVapotherm IncFeb 9, 202113G/AOld format–––SEC